Royalty Pharma plc Class A Ordinary Shares (RPRX)
Royalty Pharma plc Class A Ordinary Shares
XNAS:RPRX
39.73
$43.20 - 15.00
$38.40 - 1.00
$38.97
$39.86
$39.15
$39.15
41.24
24.05
7913864
4906013.7
336961098.14
Chart
TendieTensor AI Analysis
Company
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Fundamentals
99
22.718435
2.657360
2.214951
100
432.29M
427.25M
Technicals
Short Interest
—
—
—
Higher = harder to cover
—
Prev: —
—
—
5D avg: —
—
Discussion
Login to participate in discussions.
Recent News
Related Stocks
Based on the portfolios of people who own RPRX. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.